Fibrinogen. Cardiovascular risk factor or marker?;Fibrinógeno. ¿Factor o indicador de riesgo cardiovascular?

Archivos de Cardiologia de Mexico

Volumn 76, Issue SUPPL. 4, 2006, Pages

  Canseco Ávila, Luis M ^a   Jerjes Sánchez Díaz, Carlos ^b,c   Ortiz López, Rocío ^a   Rojas Martínez, Augusto ^a   Guzmán Ramírez, Denisse ^b  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Unidad de Investigación Clínica en Medicina S C Santander 316   (Mexico)

Author keywords

Atherogenesis; Cardiovascular risk factors; Cardiovascular risk markers; Fibrinogen; Inflammation; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; MEDICAL PRACTICE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SMOKING; SOCIOECONOMICS; THROMBOSIS; ADULT; AGE; AGED; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; EXERCISE; FEMALE; FOLLOW UP; GENETICS; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ANTILIPEMIC AGENTS; ASPIRIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; CROSS-OVER STUDIES; EXERCISE; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS;

EID: 34047263217     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. LIBBY P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
2. ROSS R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. KOENIG W: Fibrin (ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
4. KAMATH S, LIP GY: Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003; 96: 711-729.
5. YOUNG E, PRINS M, LEVINE MN, HIRSH J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643.
6. COHEN M, ARJOMAND H, POLLACK CV JR: The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction. Am J Emerg Med 2004; 22: 14-23.
7. STEC JJ, SILBERSHATZ H, TOFLER GH, MATHENEY TH, SUTHERLAND P, LIPINSKA I, ET AL: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the framingham offspring population. Circulation 2000; 102: 1634-1638.
8. DOOLITTLE RF, SPRAGGON G, EVERSE SJ: Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol 1998; 8: 792-798.
9. HERRICK S, BLANC-BRUDE O, GRAY A, LAURENT G: Fibrinogen. Int J Biochem Cell Biol 1999; 31: 741-46.
10. HAIDARIS PJ, FRANCIS CW, SPORN LA, ARVAN DS, COLLICHIO FA, MARDER VJ: Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. Blood 1989; 74: 743-750.
11. ROSENSON RS: Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22: 933-940.
12. BAUMANN H, RICHARDS C, GAULDIE J: Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987; 139: 4122-4128.
13. ESPINOSA RA: Grupo FRICVE. [Fibrinogen: cardiovascular risk factor]. Invest Clin 2002; 43: 291-301.
14. MCRITCHIE DI, GIROTTI MJ, GLYNN MF, GOLDBERG JM, ROTSTEIN OD: Effect of systemic fibrinogen depletion on intraabdominal abscess formation. J Lab Clin Med 1991; 118: 48-55.
15. ALTIERI DC, BADER R, MANNUCCI PM, EDGINGTON TS: Oligospecificity of the cellular adhesion receptor Mac-1 encompasses inducible recognition specificity for fibrinogen. J Cell Biol 1988; 107: 1893-1900.
16. COLMAN RW: Interactions between the contact system, neutrophils and fibrinogen. Adv Exp Med Biol 1990; 281: 105-120.
17. ALTIERI DC, AGBANYO FR, PLESCIA J, GINSBERG MH, EDGINGTON TS, PLOW EF: A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J Biol Chem 1990; 265: 12119-12122.
18. FORSYTH CB, SOLOVJOV DA, UGAROVA TP, PLOW EF: Integrin alpha (M) beta (2)-mediated cell migration to fibrinogen and its recognition peptides. J Exp Med 2001; 193: 1123-1133.
19. RUBEL C, FERNANDEZ GC, DRAN G, BOMPADRE MB, ISTURIZ MA, PALERMO MS: Fibrinogen promotes neutrophil activation and delays apoptosis. J Immunol 2001; 166: 2002-2010.
20. VAN DE STOLPE A, JACOBS N, HAGE WJ, TERTOOLEN L, VAN KOOYK Y, NOVAKOVA IR, ET AL: Fibrinogen binding to ICAM-1 on EA.hy 926 endothelial cells is dependent on an intact cytoskeleton. Thromb Haemost 1996; 75: 182-189.
21. DUPERRAY A, LANGUINO LR, PLESCIA J, MCDOWALL A, HOGG N, CRAIG AG, ET AL: Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem 1997; 272: 435-441.
22. HARLEY SL, STURGE J, POWELL JT: Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 652-658.
23. Gardiner EE, D' Souza SE: A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1. J Biol Chem 1997; 272: 15474-15480.
24. SMITH EB: Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15: 355-370.
25. LEVENSON J, GIRAL P, RAZAVIAN M, GARIEPY J, SIMON A: Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15: 1263-1268.
26. HICKS RC, GOLLEDGE J, MIR-HASSEINE R, POWELL JT: Vasoactive effects of fibrinogen on saphenous vein. Nature 1996; 379: 818-820.
27. RETZINGER GS, DEANGLIS AP, PATUTO SJ: Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. Arterioscler Thromb Vasc Biol 1998; 18: 1948-1957.
28. SCHNEIDER DJ, TAATJES DJ, HOWARD DB, SOBEL BE: Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol 1999; 33: 261-266.
29. FATAH K, HAMSTEN A, BLOMBACK B, BLOMBACK M: Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
30. MONTALESCOT G, COLLET JP, CHOUSSAT R, THOMAS D: Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19(Suppl H): H11-17.
31. KOENIG W, HOMBACH V, ERNST E, SUND M, MRAZ W, KEIL U: Plasma viscosity as a cardiovascular risk factor. Circulation 1992; 86: 1045.
32. KOENIG W, ERNST E: The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94: 93-107.
33. ERNST E: Fibrinogen as a cardiovascular risk factor - interrelationship with infections and inflammation. Eur Heart J 1993; 14(Suppl K): 82-87.
34. ERNST E, RESCH KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
35. HUMPHRIES SE, COOK M, DUBOWITZ M, STIRLING Y, MEADE TW: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-1455.
36. HAMSTEN A, ISELIUS L, DE FAIRE U, BLOMBACK M: Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 2: 988-991.
37. KANT JA, FORNACE AJ, JR, SAXE D, SIMON MI, MCBRIDE OW, CRABTREE GR: EvoLution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-2348.
38. YU S, SHER B, KUDRYK B, REDMAN CM: Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-10581.
39. THOMAS AE, GREEN FR, KELLEHER CH, WILKES HC, BRENNAN PJ, MEADE TW, ET AL: Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-490.
40. LACOVIELLO L, VISCHETTI M, ZITO F, BENEDETTA DONATI M: Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-1203.
41. FELLOWES AP, BRENNAN SO, GEORGE PM: Identification and characterization of five new fibrinogen gene polymorphisms. Ann NY Acad Sci 2001; 936: 536-541.
42. DE MAAT MP, KASTELEIN JJ, JUKEMA JW, ZWINDERMAN AH, JANSEN H, GROENEMEIER B, ET AL: -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18: 265-271.
43. BEHAGUE I, POIRIER O, NICAUD V, EVANS A, ARVEILER D, LUC G, ET AL: Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93: 440-449.
44. SCARABIN PY, BARA L, RICARD S, POIRIER O, CAMBOU JP, ARVEILER D, ET AL: GENetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 1993; 13: 886-891.
45. BERG K, KIERULF P: DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 1989; 36: 229-35.
46. CONNOR JM, FOWKES FG, WOOD J, SMITH FB, DONNAN PT, LOWE GD: Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet 1992; 29: 480-482.
47. TYBJAERG-HANSEN A, AGERHOLM-LARSEN B, HUMPHRIES SE, ABILDGAARD S, SCHNOHR P, NORDESTGAARD BG: A common mutation (G-455-> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-3039.
48. FOLSOM AR: Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinolysis 1999; 10(Suppl 1): S13-16.
49. SCARABIN PY, AILLAUD MF, AMOUYEL P, EVANS A, LUC G, FERRIERES J, ET AL: Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80: 749-756.
50. KROBOT K, HENSE HW, CREMER P, EBERLE E, KEIL U: Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. Arterioscler Thromb 1992; 12: 780-788.
51. PRISCO D, FEDI S, BRUNELLI T, CELLAI AP, HAGI MI, GIANNI R, ET AL: Fibrinogen and factor VIIag in healthy adolescents: the Floren-teen (Florence teenager) Study. Thromb Haemost 1996; 75: 778-781.
52. TARALLO P, HENNY J, GUEGUEN R, SIEST G: Reference limits of plasma fibrinogen. Eur J Clin Chem Clin Biochem 1992; 30: 745-751.
53. LAHARRAGUE PF, CAMBUS JP, FILLOLA G, CORBERAND JX: Plasma fibrinogen and physiological aging. Aging 1993; 5: 445-449.
54. GIANSANTE C, FIOTTI N, CATTIN L, DA COL PG, CALABRESE S: Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost 1994; 71: 581-586.
55. ISHIKAWA S, KARIO K, NAGO N, KAYABA K, HIRAOKA J, MATSUO H, ET AL: Factor VII and fibrinogen levels examined by age, sex, and other atherosclerotic risk factors in a Japanese population. The Jichi Medical School Cohort Study. Thromb Haemost 1997; 77: 890-893.
56. BALLEISEN L, BAILEY J, EPPING PH, SCHULTE H, VAN DE LOO J: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479.
57. FU A, SREEKUMARAN NAIR K: Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol 1998; 275: E1023-1030.
58. DITSCHUNEIT HH, FLECHTNER-MORS M, ADLER G: Fibrinogen in obesity before and after weight reduction. Obes Res 1995; 3: 43-48.
59. CRAVERI A, TORNAGHI G, PAGANARDI L, RANIERI R, LEONARDI G, DI BELLA M: [Hemorrheologic disorders in obese patients. Study of the viscosity of the blood, erythrocytes, plasma, fibrinogen and the erythrocyte filtration index]. Minerva Med 1987; 78: 899-906.
60. PRIMROSE JN, DAVIES JA, PRENTICE CR, HUGHES R, JOHNSTON D: Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399.
61. CARROLL S, COOKE CB, BUTTERLY RJ: Plasma viscosity, fibrinogen and the metabolic syndrome: effect of obesity and cardiorespiratory fitness. Blood Coagul Fibrinolysis 2000; 11: 71-78.
62. IMPERATORE G, RICCARDI G, IOVINE C, RIVELLESE AA, VACCARO O: Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998; 21: 649-654.
63. EL-SAYED MS, JONES PG, SALE C: Exercise induces a change in plasma fibrinogen concentration: fact or fiction? Thromb Res 1999; 96: 467-472.
64. RANKINEN T, VAISANEN S, PENTTILA I, RAURAMAA R: Acute dynamic exercise increases fibrinolytic activity. Thromb Haemost 1995; 73: 281-286.
65. ZANETTINI R, BETTEGA D, AGOSTONI O, BALLESTRA B, DEL ROSSO G, DI MICHELE R, ET AL: Exercise training in mild hypertension: effects on blood pressure, left ventricular mass and coagulation factor VII and fibrinogen. Cardiology 1997; 88: 468-473.
66. SCHUIT AJ, SCHOUTEN EG, KLUFT C, DE MAAT M, MENHEERE PP, KOK FJ: Effect of strenuous exercise on fibrinogen and fibrinolysis in healthy elderly men and women. Thromb Haemost 1997; 78: 845-851.
67. IMHOF A, KOENIG W: Exercise and thrombosis. Cardiol Clin 2001; 19: 389-400.
68. VERISSIMO MT, ARAGAO A, SOUSA A, BARBOSA B, PALMEIRO A, ANTUNES F, ET AL: Physical excercise and thrombotic risk in the elderly. Rev Port Cardiol 2001; 20: 625-639.
69. CONNELLY JB, COOPER JA, MEADE TW: Strenuous exercise, plasma fibrinogen, and factor VII activity. Br Heart J 1992; 67: 351-354.
70. CRAWFORD VL, MCNERLAN SE, STOUT RW: Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Aging 2003; 32: 661-665.
71. HERMIDA RC, CALVO C, AYALA DE, LOPEZ JE, FERNANDEZ JR, MOJON A, ET AL: Seasonal variation of fibrinogen in dipper and nondipper hypertensive patients. Circulation 2003; 108: 1101-1106.
72. MAVRI A, GUZIC-SALOBIR B, SALOBIR- PAJNIC B, KEBER I, STARE J, STEGNAR M: Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease. Blood Coagul Fibrinolysis 2001; 12: 359-365.
73. VAN DER BOM JG, DE MAAT MP, BOTS ML, HAVERKATE F, DE JONG PT, HOFMAN A, ET AL: Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998; 18(4): 621-625.
74. STEPTOE A, KUNZ-EBRECHT S, OWEN N, FELDMAN PJ, RUMLEY A, LOWE GD, ET AL: Influence of socioeconomic status and job control on plasma fibrinogen responses to acute mental stress. Psychosom Med 2003; 65: 137-144.
75. BRUNNER E, DAVEY SMITH G, MARMOT M, CANNER R, BEKSINSKA M, O'BRIEN J: Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008-1013.
76. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Task Force on Oral Contraceptives - WHO Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Br J Obstet Gynaecol 1991; 98: 1117-1128.
77. ERNST E: Oral contraceptives, fibrinogen and cardiovascular risk. Atherosclerosis 1992; 93: 1-5.
78. LEE AJ, LOWE GD, SMITH WC, TUNSTALL-PEDOE H: Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993; 83: 616-621.
79. MEADE TW, HAINES AP, IMESON JD, STIRLING Y, THOMPSON SG: Menopausal status and haemostatic variables. Lancet 1983; 1: 22-24.
80. FROHLICH M, SCHUNKERT H, HENSE HW, TROPITZSCH A, HENDRICKS P, DORING A, ET AL: Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 1998; 100: 577-581.
81. NORRIS LA, JOYCE M, O'KEEFFE N, SHEPPARD BL, BONNAR J: Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002; 43: 125-133.
82. CONARD J, GOMPEL A, PELISSIER C, MIRABEL C, BASDEVANT A: Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 1997; 68: 449-453.
83. LIP GY, BLANN AD, JONES AF, BEEVERS DG: Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764-771.
84. ELIASSON M, ASPLUND K, EVRIN PE, LUNDBLAD D: Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995; 113: 41-53.
85. CIGOLINI M, TARGHER G, DE SANDRE G, MUGGEO M, SEIDELL JC: Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. Eur J Clin Invest 1994; 24: 126-130.
86. KANNEL WB, D'AGOSTINO RB, BELANGER AJ: Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987: 113: 1006-1010.
87. ISO H, SHIMAMOTO T, SATO S, KOIKE K, IIDA M, KOMACHI Y: Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol 1996; 144: 1151-1154.
88. FISHER SD, ZAREBA W, MOSS AJ, MARDER VJ, SPARKS CE, HOCHMAN J, ET AL: Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction. Am J Cardiol 2000; 86: 813-818.
89. HUNTER KA, GARLICK PJ, BROOM I, ANDERSON SE, MCNURLAN MA: Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci 2001; 100: 459-465.
90. DAS I: Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985; 153: 9-13.
91. MCCARTY MF: Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999; 52: 465-477.
92. CASTELL JV, GOMEZ-LECHON MJ, DAVID M, ANDUS T, GEIGER T, TRULLENQUE R, ET AL: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-239.
93. MARINKOVIC S, JAHREIS GP, WONG GG, BAUMANN H: IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989; 142: 808-812.
94. ZITO F, DI CASTELNUOVO A, D'ORAZIO A, NEGRINI R, DE LUCIA D, DONATI MB, ET AL: Helicobacter pylori infection and the risk of myocardial infarction: role of fibrinogen and its genetic control. Thromb Haemost 1999; 82: 14-18.
95. WONG YK, DAWKINS KD, WARD ME: Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-1439.
96. COOK PJ, HONEYBOURNE D, LIP GY, BEEVERS DG, WISE R, DAVIES P: Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham Stroke Project. Stroke 1998; 29: 404-410.
97. COOK PJ, LIP GY, DAVIES P, BEEVERS DG, WISE R, HONEYBOURNE D: Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589-594.
98. YARNELL JW, BAKER IA, SWEETNAM PM, BAINTON D, O'BRIEN JR, WHITEHEAD PJ, ET AL: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 836-844.
99. PATEL P, MENDALL MA, CARRINGTON D, STRACHAN DP, LEATHAM E, MOLINEAUX N, ET AL: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-714.
100. REGNSTROM J, JOVINGE S, BAVENHOLM P, ERICSSON CG, DE FAIRE U, HAMSTEN A, ET AL: Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998; 243: 109-113.
101. KOENIG W, ROTHENBACHER D, HOFFMEISTER A, MILLER M, BODE G, ADLER G, ET AL: Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. Circulation 1999; 100: 2326-2331.
102. TOSS H, GNARPE J, GNARPE H, SIEGBAHN A, LINDAHL B, WALLENTIN L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998; 19: 570-577.
103. HOFFMEISTER A, ROTHENBACHER D, WANNER P, BODE G, PERSSON K, BRENNER H, ET AL: Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study. J Am Coll Cardiol 2000; 35: 112-118.
104. MEADE TW, NORTH WR, CHAKRABARTI R, STIRLING Y, HAINES AP, THOMPSON SG, ET AL: Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054.
105. MEADE TW, MELLOWS S, BROZOVIC M, MILLER GJ, CHAKRABARTI RR, NORTH WR, ET AL: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
106. WILHELMSEN L, SVARDSUDD K, KORSAN- BENGTSEN K, LARSSON B, WELIN L, TIBBLIN G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
107. STONE MC, THORP JM: Plasma fibrinogen-a major coronary risk factor. J R Coll Gen Pract 1985; 35: 565-569.
108. BALLEISEN L, SCHULTE H, ASSMANN G, EPPING PH. VAN DE LOO J: Coagulation factors and the progress of coronary heart disease. Lancet 1987; 2: 461-463.
109. BAKER IA, SWEETNAM PM, YARNELL JW, BAINTON D, ELWOOD PC: Haemostatic and other risk factors for ischaemic heart disease and social class: evidence from the Caerphilly and Speedwell studies. Int J Epidemiol 1988; 17: 759-765.
110. KANNEL WB, WOLF PA, CASTELLI WP, D'AGOSTINO RB: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-1186.
111. BALLEISEN L, BAILEY J, EPPING PH, SCHULTE H, VAN DE LOO J: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479.
112. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41: 105-114.
113. LEE AJ, LOWE GD, WOODWARD M, TUNSTALL-PEDOE H: Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-342.
114. FOLSOM AR, WU KK, SHAHAR E, DAVIS CE: Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 1993; 13: 1829-1836.
115. SHARP DS, ABBOTT RD, BURCHFIEL CM, RODRIGUEZ BL, TRACY RP, YANO K. ET AL: Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 1996; 16: 262-268.
116. SMITH FB, LEE AJ, FOWKES FG, PRICE JF, RUMLEY A, LOWE GD: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Arten-Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-3325.
117. YANO K, GROVE JS, CHEN R, RODRIGUEZ BL, CURB JD, TRACY RP: Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 2001; 21: 1065-1070.
118. STEC JJ, SILBERSHATZ H, TOFLER GH, MATHENEY TH, STEC JJ, SILBERSHATZ H. ET AL: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the framingham offspring population. Circulation 2000; 102: 1634.
119. SANCHIS J, BODI V, NAVARRO A, LLACER A, BLASCO M, MAINAR L, ET AL: [Prognostic factors in unstable angina with dynamic electrocardiographic changes. Value of fibrinogen]. Rev Esp Cardiol 2002; 55: 921-927.
120. ARNAU VIVES MA, RUEDA SORIANO J, MARTINEZ DOLZ LV, OSA SAEZ A, ALMENAR BONET L, MORILLAS BLASCO P, ET AL: [Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-q-wave myocardial infarction]. Rev Esp Cardiol 2002; 55: 622-630.
121. TOSS H, LINDAHL B, SIEGBAHN A, WALLENTIN L: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204-4210.
122. PALMIERI V, CELENTANO A, ROMAN MJ, DE SIMONE G, LEWIS MR, BEST L, ET AL: Fibrinogen and pre-clinical echocardiography target organ damage: the strong heart study. Hypertension 2001; 38: 068-1074.
123. THOMPSON SG, KIENAST J, PYKE SD, HAVERKATE F, VAN DE LOO JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 35-641.
124. IZAGUIRRE AVILA R, ZALDIVAR ALCANTARA H: Fibrinógeno como factor de riesgo. Arch Cardiol Mex 2003; 73: 7-10.
125. ACEVEDO M, PEARCE GL, KOTTKE-MARCHANT K, SPRECHER DL: Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 1042-1045.
126. KOCKX M, GERVOIS PP, POULAIN P, DERUDAS B, PETERS JM, GONZALEZ FJ, ET AL: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999; 93: 2991-2998.
127. STAELS B, KOENIG W, HABIB A, MERVAL R, LEBRET M, TORRA IP, ET AL: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793.
128. FLETCHER A, ALKJAERSIG N, SCHONFELD G, WITZTUM J: Fibrinogen catabolism inpatients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings. Arteriosclerosis 1981; 1: 202-209.
129. ROSENSON RS, TANGNEY CC, SCHAEFER EJ: Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155: 463-466.
130. SIDHU JS, COWAN D, KASKI JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
131. IVANOVA K, SCHAEFER M, DRUMMER C, GERZER R: Effects of nitric oxide-containing compounds on increases in cytosolic ionized Ca2+ and on aggregation of human platelets. Eur J Pharmacol 1993; 244: 37-47.
132. LOSCALZO J: Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 1992; 70: 18B-22B.
133. BASSENGE E: Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors. Eur Heart J 1991; 12(Suppl E): 12-15.
134. PRISCO D, PANICCIA R, BANDINELLI B, GORI AM, ATTANASIO M, GIUSTI B, ET AL: Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Int J Clin Lab Res 1998; 28: 170-173.
135. YOUNG E, PODOR TJ, VENNER T, HIRSH J: Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997; 17: 1568-1574.
136. COSMI B, FREDENBURGH JC, RISCHKE J, HIRSH J, YOUNG E, WEITZ JI: Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997; 95: 118-124.
137. BRUGEMANN J, VAN DER MEER J, TAKENS BH, HILLEGE H, LIE KI: A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction. Br Heart J 1990; 64: 355-358.
138. KANNEL WB, D'AGOSTINO RB, WILSON PW, BELANGER AJ, GAGNON DR: Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-676.
139. STONE MC, THORP JM: Plasma fibrinogen-a major coronary risk factor. JR Coll Gen Pract 1985; 35: 565-569.
140. HEINRICH J, BALLEISEN L, SCHULTE H, ASSMANN G, VAN DE LOO J: Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 1: 54-59.
141. MOLLER L, KRISTENSEN TS: Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler Thromb 1991; 11: 344-350.
142. YARNELL JW, SWEETNAM PM, ELWOOD PC, EASTHAM R, GILMOUR RA, O'BRIEN JR, ET AL: Haemostatic factors and ischaemic heart disease. The Caerphilly study. Br Heart J 1985; 53: 483-487.
143. BAKER IA, EASTHAM R, ELWOOD PC, ETHERINGTON M, O'BRIEN JR, SWEETNAM PM: Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell study. Br Heart J 1982; 47: 490-494.
144. ASSMANN G, CULLEN P, HEINRICH J, SCHULTE H: Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32: 364-370.
145. CREMER P, NAGEL D, LABROT B, MANN H, MUCHE R, ELSTER H, ET AL: Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-453.
146. BARRON HV, CANNON CP, MURPHY SA, BRAUNWALD E, GIBSON CM: Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction. Circulation 2000; 102: 2329-2334.
147. YARNELL JWG, PATTERSON CC, SWEETNAM PM, LOWE GDO: Haemostatic/inflammatory markers predict 10-year risk of IHD at lest as well as lipids: the Caerphilly collaborative studies. Eur Heart J 2004; 25: 1049-1056.